Delcath

Delcath Systems is a commercial-stage company with a mission to revolutionize the treatment of primary and metastatic liver cancers through its proprietary Hepatic Delivery System (HDS). Its landmark achievement is the FDA approval of HEPZATO KIT™ (melphalan/HDS) for metastatic uveal melanoma (mUM), a rare and aggressive cancer with limited options. The company's strategy is to drive commercial adoption in mUM while aggressively pursuing label expansion into high-prevalence liver-dominant cancers like metastatic colorectal and breast cancer through ongoing Phase 2 trials, leveraging its unique regional chemotherapy delivery platform.

The Hepatic Delivery System (HDS) is a minimally-invasive, closed-loop platform for Percutaneous Hepatic Perfusion (PHP), enabling high-dose, regional chemotherapy delivery to the liver with concurrent filtration of venous blood to reduce systemic exposure and toxicity.